Erras Alaa, Shahrvini Bita, Weinreb Robert N, Baxter Sally L
Hamilton Glaucoma Center, Shiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA.
Hamilton Glaucoma Center, Shiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA
Br J Ophthalmol. 2023 Feb;107(2):153-159. doi: 10.1136/bjophthalmol-2020-317918. Epub 2021 Apr 15.
Current glaucoma treatments aim to lower intraocular pressure, often with topical ocular hypotensive medications. Unfortunately, the effectiveness of these medications depends on sustained patient adherence to regimens which may involve instilling multiple medications several times daily. Patient adherence to glaucoma medications is often low. Recent innovations in digital sensor technologies have been leveraged to confirm eyedrop medication usage in real-time and relay this information back to providers. Some sensors have also been designed to deliver medication reminders and notifications as well as assist with correct eyedrop administration technique. Here, we review recent innovations targeted at improving glaucoma medication adherence and discuss their limitations.
目前的青光眼治疗旨在降低眼压,通常使用局部降眼压药物。不幸的是,这些药物的有效性取决于患者持续坚持治疗方案,而这可能涉及每天多次滴入多种药物。患者对青光眼药物的依从性往往较低。数字传感器技术的最新创新已被用于实时确认眼药水的使用情况,并将这些信息反馈给医疗服务提供者。一些传感器还被设计用于发送用药提醒和通知,以及协助正确的眼药水给药技术。在此,我们回顾了旨在提高青光眼药物依从性的最新创新,并讨论了它们的局限性。